히드로코르티손 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the hydrocortisone market size is projected to expand from USD 1.76 billion in 2025 and USD 1.82 billion in 2026 to USD 2.25 billion by 2031, registering a CAGR of 4.28% between 2026 to 2031.

This report is Segmented by Route of Administration (Topical, Oral, and Others), by Prescription Type (Over-The-Counter (OTC), Prescription (Rx)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Indication (Dermatology, Gastrointestinal, and Others), and by Geography (North America, Europe, Asia-Pacific, and Others). The Report Offers the Value (USD) for the Above Segments.

Global Hydrocortisone Market Trends and Insights

WHO Essential Medicines Status Ensures Baseline Demand and Formulary Inclusion

Hydrocortisone's presence on the 24th WHO Model List of Essential Medicines, reaffirmed in September 2025, secures priority in national procurement and public formularies across income levels, which stabilizes the hydrocortisone market against abrupt displacement in tender-driven settings. The 10th WHO Model List of Essential Medicines for Children in 2025 codified broader pediatric coverage, including oral liquid 1 mg/mL, oral granules, and injectables, aligning supply with pediatric replacement needs and mitigating dosing workarounds that previously eroded adherence. Country lists in Africa and other regions mirror these inclusions, anchoring availability from primary care posts to tertiary hospitals and reinforcing sustained baseline volumes for both oral and parenteral formats. Ongoing WHO Expert Committee reviews in 2026 keep the competitive bar active for overlapping therapies. Yet, hydrocortisone's physiologic replacement role and emergency-use relevance make removal risk low in the near term. This status enhances access while constraining pricing power in public channels, which shapes a predictable but cost-sensitive foundation for the hydrocortisone market.

OTC Availability Enables Self-Care and Retail/E-Pharmacy Access Expansion

OTC hydrocortisone at 0.5-1% strength enables routine self-management of minor dermatoses without physician visits, supporting the largest 2025 prescription-type share and aligning with consumer preference for low-friction access, which together reinforce volume resilience across retail and digital channels. The United States FDA's Additional Conditions for Nonprescription Use framework, effective in January 2025, allows technology-enabled self-selection for certain OTC medicines, which supports safe self-care journeys and can lift conversion among consumers who otherwise defer treatment. Growth is moderated by rising consumer awareness of topical steroid withdrawal risks, which encourages some users to prefer non-steroidal options, but convenient OTC access still anchors front-line care for mild inflammation.

Generic Price Pressure and Intense Competition Compress Margins

Hydrocortisone is widely produced across oral, topical, and parenteral forms by many manufacturers, which intensifies price competition and narrows transaction margins across channels without significantly lifting unit volumes in mature indications. Supply-chain events underscore fragility in certain presentations, as the United Kingdom signaled shortages of pre-mixed hydrocortisone injection in 2025and advised substitution with sodium succinate powder for injection that is suitable for kit assembly, which preserved emergency-kit readiness but highlighted single-supplier risk. In this environment, the hydrocortisone market remains volume-stable but price-sensitive, and manufacturers increasingly prioritize niche, margin-protected formulations to defend profitability.

Other drivers and restraints analyzed in the detailed report include:

1. Guideline-Backed Use in Vasopressor-Refractory Septic Shock Sustains Parenteral Demand
2. Pediatric-Specific Approvals Enhance Access and Drive Oral Segment Growth
3. Adverse Effects and Steroid-Phobia/TSW Reduce Adherence and Appropriate Use

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Topical administration accounted for 54.68% of 2025 revenue on the strength of OTC and prescription use in dermatology, while oral formulations are projected to grow fastest at 5.98% CAGR through 2031 as pediatric-specific products enable precise dosing and reduce caregiver variability, a dynamic that supports the hydrocortisone market size outlook through the forecast period. Eton's KHINDIVI oral solution for patients aged 5 and older received FDA approval in May 2025 and launched with specialty pharmacy support, complementing ALKINDI SPRINKLE granules and improving dosing accuracy in a population where precision is clinically important. The KHINDIVI label excludes children under 5 due to excipient risks, which narrows its on-label reach but reinforces the clinical rationale for age-tailored formulations within the hydrocortisone market. WHO EMLc 2025 includes oral liquids and granules alongside tablets, providing a policy foundation for broader pediatric access in markets where essential medicines lists steer procurement.

Topical hydrocortisone continues to dominate front-line management of mild inflammatory dermatoses, supported by OTC access, patient familiarity, and clinician comfort with lowest-potency regimens in sensitive areas where risk-benefit profiles are favorable for limited durations. Rectal delivery is positioned for targeted gastrointestinal use, where Cristcot's next-generation 90 mg hydrocortisone acetate suppository progressed to an FDA decision and reported remission benefits in Phase 3 results disclosed at NDA acceptance, expanding options for distal ulcerative colitis. Across modalities, the hydrocortisone industry is concentrating investment in delivery improvements that minimize systemic exposure while preserving efficacy for localized indications, a strategy aimed at creating durable niches inside a generics-heavy field. Emergency-focused delivery tools, including efforts to simplify rapid dosing outside clinical settings, reflect parallel emphasis on safety and readiness for adrenal crisis. This mix of entrenched topical leadership and rising oral precision dosing strengthens the hydrocortisone market's footing across hospital and home settings as clinical needs diversify

OTC products accounted for a 57.88% of 2025 revenue by enabling rapid, low-friction access for mild symptoms. Still, prescription pathways are projected to grow faster at 6.34% CAGR through 2031 as specialized formulations expand care in pediatrics, ulcerative colitis, and critical care, which together diversify the hydrocortisone market. Specialty distribution and copay programs around pediatric solutions help reduce barriers to adherence and position Rx hydrocortisone as a precision tool rather than a commodity choice, which underpins the growth gap with OTC. Rx-only parenteral presentations are insulated from OTC substitution because they are procedure-based in ICUs and emergency departments, where protocol adherence prioritizes on-formulary availability and consistency. OTC hydrocortisone remains a cornerstone in self-managed dermatology due to convenience, cost access, and widespread product familiarity, features that reinforce volume leadership even as clinical vigilance around topical steroid withdrawal rises. In parallel, Rx channels capture value through formulations and indications that require physician supervision or precise dosing that cannot be replicated in over-the-counter formats, which balances the hydrocortisone market across price tiers and care settings. Over the forecast, differentiated Rx products and hospital-driven uses maintain faster growth as they address clinical niches that are less exposed to consumer sentiment swings. At the same time, OTC continues to absorb the broad base of minor inflammatory presentations.

Geography Analysis

North America held 38.34% of revenue in 2025 as pediatric precision dosing matured and hospital protocols remained firmly embedded, while Asia Pacific is projected to deliver the fastest CAGR at 5.21% through 2031, a two-speed pattern that shapes the hydrocortisone market across reimbursement, access, and channel maturity. The United States and Canadian healthcare systems maintain injectable hydrocortisone in hospital formularies for emergency use in adrenal crisis and shock management. Pediatric adrenal insufficiency is managed with chronic hydrocortisone replacement, including liquid and compounded formulations when needed, supported through standard pharmacy and compounding channels, resulting in ongoing prescription requirements in affected patients. Digital pharmacy expansion and same-day logistics widen convenient access for patients and caregivers, while clinical groups and regulators continue to update safety communications to ensure appropriate topical steroid use. The North American hydrocortisone market is being shaped by ongoing innovation in corticosteroid formulations for inflammatory bowel diseases, particularly ulcerative colitis. For instance, as per the article published in MJH Life Sciences in April 2026, the FDA's acceptance of an NDA for a next-generation hydrocortisone acetate suppository for ulcerative colitis of the rectum highlights a key driver rising demand for targeted, locally acting therapies that improve efficacy while reducing systemic side effects in chronic GI conditions. Overall, increasing regulatory support for advanced rectal corticosteroid delivery systems and the unmet need for effective localized ulcerative colitis treatments are expected to be major growth drivers for the North America hydrocortisone market.

Asia Pacific's growth reflects rising urbanization, penetration of generic hydrocortisone across retail and hospital settings, and rapid adoption of pharmacy e-commerce and telepharmacy services that together strengthen continuity of care for chronic needs like adrenal replacement.

List of Companies Covered in this Report:

1. Amneal Pharmaceuticals
2. ANI Pharmaceuticals
3. BluePoint Laboratories
4. Chartwell RX, LLC
5. Cipla
6. Hikma Pharmaceuticals
7. Medrock Pharmacy LLC
8. Perrigo Company
9. Pfizer
10. Sandoz Group
11. Sanofi
12. Taro Pharmaceutical Industries Ltd.
13. Teva Pharmaceutical Industries
14. Trifecta Pharmaceuticals USA, LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 WHO Essential Medicines Status Ensures Baseline Demand and Formulary Inclusion
  • 4.2.2 OTC Availability (0.5-1%) Enables Self-care and Retail/e-pharmacy Access Expansion
  • 4.2.3 Guideline-backed Use in Vasopressor-refractory Septic Shock (parenteral demand)
  • 4.2.4 Emergency Adrenal Crisis Protocols Mandate Hydrocortisone Kits and Rapid Dosing
  • 4.2.5 Pediatric-specific Approvals (Oral Granules/Solution) for Adrenal Insufficiency
  • 4.2.6 Endocrine Tapering/Stress-dose Guidance Favors Hydrocortisone in GIAI Management
• 4.3 Market Restraints
  • 4.3.1 Adverse Effects and Steroid-phobia/TSW Reduce Adherence and Appropriate Use
  • 4.3.2 Generic Price Pressure and Intense Competition Compress Margins
  • 4.3.3 Steroid-sparing Biologics/JAK Inhibitors Displace Use in Select Indications
  • 4.3.4 Pediatric Sepsis Guidance Limits Routine Hydrocortisone; Retail Curbs on Misuse
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Route of Administration
  • 5.1.1 Topical
  • 5.1.2 Oral
  • 5.1.3 Others (Rectal, Parenteral, etc.)
• 5.2 By Prescription Type
  • 5.2.1 Over-the-Counter (OTC)
  • 5.2.2 Prescription (Rx)
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies
  • 5.3.3 Online Pharmacies
• 5.4 By Indication
  • 5.4.1 Dermatology
  • 5.4.2 Gastrointestinal
  • 5.4.3 Others (Ophthalmic, Allergic reacttions, etc.)
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.4.1 Amneal Pharmaceuticals, Inc.
  • 6.4.2 ANI Pharmaceuticals, Inc.
  • 6.4.3 BluePoint Laboratories
  • 6.4.4 Chartwell RX, LLC
  • 6.4.5 Cipla Ltd.
  • 6.4.6 Hikma Pharmaceuticals PLC
  • 6.4.7 Medrock Pharmacy LLC
  • 6.4.8 Perrigo Company plc
  • 6.4.9 Pfizer Inc.
  • 6.4.10 Sandoz
  • 6.4.11 Sanofi
  • 6.4.12 Taro Pharmaceutical Industries Ltd.
  • 6.4.13 Teva Pharmaceutical Industries Ltd.
  • 6.4.14 Trifecta Pharmaceuticals USA, LLC

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment